deltatrials
Completed PHASE4 INTERVENTIONAL 2-arm NCT02661217

Comparison of Pre- and Post-discharge Initiation of LCZ696 Therapy in HFrEF Patients After an Acute Decompensation Event (TRANSITION)

A Multicenter, Randomized, Open Label, Parallel Group Study Comparing Pre-discharge and posT-discharge tReatment Initiation With LCZ696 in heArt Failure patieNtS With Reduced ejectIon-fracTion hospItalized for an Acute decOmpensation eveNt (ADHF)

Sponsor: Novartis Pharmaceuticals

Conditions Heart Failure With Reduced Ejection Fraction
Interventions LCZ696
Updated 18 times since 2017 Last updated: Mar 29, 2021 Started: Feb 12, 2016 Primary completion: Feb 20, 2018 Completion: Jun 20, 2018
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Heart Failure With Reduced Ejection Fraction, this trial is completed. The trial is conducted by Novartis Pharmaceuticals and has accumulated 18 data snapshots since 2016. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Apr 2017 · 59 days · monthly snapshot~Apr 2017 – ~Jul 2017 · 3 months · monthly snapshot~Jul 2017 – ~Sep 2017 · 2 months · monthly snapshot~Sep 2017 – ~Oct 2017 · 30 days · monthly snapshot~Oct 2017 – ~Jan 2018 · 3 months · monthly snapshot~Jan 2018 – ~Mar 2018 · 59 days · monthly snapshot~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Feb 2019 · 7 months · monthly snapshot~Feb 2019 – ~Apr 2019 · 59 days · monthly snapshot~Apr 2019 – ~Jan 2021 · 21 months · monthly snapshot~Jan 2021 – ~May 2021 · 4 months · monthly snapshot~May 2021 – ~Jul 2024 · 38 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – ~Feb 2026 · 5 months · monthly snapshot~Feb 2026 – present · 5 months · monthly snapshot

Change History

18 versions recorded

  1. Feb 2026 — Present [monthly]

    Completed PHASE4

  2. Sep 2025 — Feb 2026 [monthly]

    Completed PHASE4

  3. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE4

  4. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE4

  5. May 2021 — Jul 2024 [monthly]

    Completed PHASE4

▶ Show 13 earlier versions

  1. Jan 2021 — May 2021 [monthly]

    Completed PHASE4

  2. Apr 2019 — Jan 2021 [monthly]

    Completed PHASE4

  3. Feb 2019 — Apr 2019 [monthly]

    Completed PHASE4

  4. Jul 2018 — Feb 2019 [monthly]

    Completed PHASE4

    Status: Active Not Recruiting → Completed

  5. Jun 2018 — Jul 2018 [monthly]

    Active Not Recruiting PHASE4

  6. Mar 2018 — Jun 2018 [monthly]

    Active Not Recruiting PHASE4

    Status: Recruiting → Active Not Recruiting

  7. Jan 2018 — Mar 2018 [monthly]

    Recruiting PHASE4

  8. Oct 2017 — Jan 2018 [monthly]

    Recruiting PHASE4

  9. Sep 2017 — Oct 2017 [monthly]

    Recruiting PHASE4

  10. Jul 2017 — Sep 2017 [monthly]

    Recruiting PHASE4

  11. Apr 2017 — Jul 2017 [monthly]

    Recruiting PHASE4

  12. Feb 2017 — Apr 2017 [monthly]

    Recruiting PHASE4

  13. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE4

    First recorded

Feb 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Novartis Pharmaceuticals
Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

A Coruña, Spain , Amadora, Portugal , Amiens, France , Ankara, Turkey (Türkiye) , Ashford, United Kingdom , Aveiro, Portugal , Barcelona, Spain , Basel, Switzerland , Basingstoke, United Kingdom , Beirut, Lebanon and 127 more locations